智通财经APP获悉，香港联交所最新数据显示，5月20日，LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5万股，每股作价226.0879港元，总金额约为2373.92万港元。增持后最新持股数目约为1175.79万股，最新持股比例为13.00%。
本交易涉及其他关联方：施毅。
补充资料：LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.